Sanofi SNY announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa ...

The company reported a robust cash position of $226.9 million as of the second quarter of 2024, following Sanofi (NASDAQ:SNY)’s acquisition of INBRX-101 for approximately $2.2 billion. InvestingPro ...

The company reported a robust cash position of $226.9 million as of the second quarter of 2024, following Sanofi (NASDAQ:SNY)'s acquisition of INBRX-101 for approximately $2.2 billion ...

Also Read: Sanofi’s Blood Cancer Drug’s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma The facility’s quality unit was also scrutinized for its inability to ...

$690,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to Pharmacy Benefit ...

(RTTNews) - Sanofi (SNYNF, SNY ... the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained 26.6% against the industry’s decline of 14.3%. The stock has also ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a trial designed to test an over-the-counter version of its erectile ...

while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY ...